MX2020005933A - Metodo y composicion para tratar la deficiencia de arginasa 1. - Google Patents
Metodo y composicion para tratar la deficiencia de arginasa 1.Info
- Publication number
- MX2020005933A MX2020005933A MX2020005933A MX2020005933A MX2020005933A MX 2020005933 A MX2020005933 A MX 2020005933A MX 2020005933 A MX2020005933 A MX 2020005933A MX 2020005933 A MX2020005933 A MX 2020005933A MX 2020005933 A MX2020005933 A MX 2020005933A
- Authority
- MX
- Mexico
- Prior art keywords
- deficiency
- composition
- arginase
- treating arginase
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03001—Arginase (3.5.3.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762594747P | 2017-12-05 | 2017-12-05 | |
| US201862725612P | 2018-08-31 | 2018-08-31 | |
| US201862745000P | 2018-10-12 | 2018-10-12 | |
| PCT/US2018/063982 WO2019113157A1 (en) | 2017-12-05 | 2018-12-05 | Method and composition for treating arginase 1 deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005933A true MX2020005933A (es) | 2021-01-15 |
Family
ID=64734275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005933A MX2020005933A (es) | 2017-12-05 | 2018-12-05 | Metodo y composicion para tratar la deficiencia de arginasa 1. |
| MX2025006207A MX2025006207A (es) | 2017-12-05 | 2020-07-13 | Composiciones que contienen arginasa i humana con un cofactor de metal de cobalto para usarse en el tratamiento de la deficiencia de arginasa 1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025006207A MX2025006207A (es) | 2017-12-05 | 2020-07-13 | Composiciones que contienen arginasa i humana con un cofactor de metal de cobalto para usarse en el tratamiento de la deficiencia de arginasa 1 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11717562B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3720476A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7827407B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR20260047622A (cg-RX-API-DMAC10.html) |
| CN (3) | CN120661640A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2018378485B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3084801A1 (cg-RX-API-DMAC10.html) |
| MX (2) | MX2020005933A (cg-RX-API-DMAC10.html) |
| TW (1) | TWI878212B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019113157A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3449935A1 (en) * | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
| TWI878212B (zh) | 2017-12-05 | 2025-04-01 | 瑞典商伊梅爾迪卡製藥公司 | 用於治療精胺酸酶1缺乏症之方法及組合物 |
| WO2020081994A1 (en) * | 2018-10-19 | 2020-04-23 | Aerase, Inc. | Arginine depletion therapy for treatment of gamt deficiency |
| BR112022003633A2 (pt) * | 2019-08-30 | 2022-06-07 | Aeglea Biotherapeutics Inc | Métodos para produção de arginase 1 recombinante humana e usos da mesma |
| CN114350721B (zh) * | 2021-11-30 | 2024-05-24 | 新泰市佳禾生物科技有限公司 | 微生物酶法生产l-鸟氨酸的方法 |
| CN114196712B (zh) * | 2021-11-30 | 2024-04-02 | 新泰市佳禾生物科技有限公司 | 一种固定化酶法生产l-鸟氨酸的方法 |
| CN114214353B (zh) * | 2021-11-30 | 2023-07-18 | 新泰市佳禾生物科技有限公司 | 一种发酵生产人重组精氨酸酶i的方法 |
| CN116179452A (zh) * | 2022-07-11 | 2023-05-30 | 山东第一医科大学(山东省医学科学院) | 一种用于治疗精氨酸酶缺乏症的工程益生菌及其构建方法和应用 |
| WO2025171346A1 (en) * | 2024-02-08 | 2025-08-14 | University Of Florida Research Foundation, Incorporated | Indoleamine 2,3-dioxygenase variants |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02117383A (ja) | 1988-10-26 | 1990-05-01 | Tosoh Corp | ヒトアルギナーゼの製造方法 |
| US5780286A (en) | 1996-03-14 | 1998-07-14 | Smithkline Beecham Corporation | Arginase II |
| WO2003063780A2 (en) | 2002-01-25 | 2003-08-07 | Cancer Treatments International | Therapeutic composition for treatment of cancer by arginine depletion |
| HK1053577A2 (en) | 2002-06-20 | 2003-10-10 | Bio-Cancer Treatment International Limited | Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation |
| GB0315248D0 (en) * | 2003-06-30 | 2003-08-06 | Hoffmann La Roche | HCV regulated protein expression |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| CN1745847A (zh) | 2004-09-08 | 2006-03-15 | 康达医药科技有限公司 | 用精氨酸酶治疗肝炎的药物组合物和方法 |
| EP1974044B1 (en) | 2005-12-12 | 2011-01-26 | CANJI, Inc. | Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase |
| PL3064579T3 (pl) | 2008-10-31 | 2021-07-05 | Aerase, Inc. | Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz |
| US9382525B2 (en) * | 2009-03-26 | 2016-07-05 | The Hong Kong Polytechnic University | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents |
| AU2010242422B2 (en) | 2009-03-26 | 2014-12-04 | The Hong Kong Polytechnic University | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents |
| CA2766039A1 (en) | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
| WO2012061015A2 (en) | 2010-11-03 | 2012-05-10 | Scott & White Healthcare | L-citrulline supplementation during arginine depletion therapy with arginase |
| CN103184209B (zh) | 2011-12-27 | 2015-09-16 | 拜奥生物科技（上海）有限公司 | 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用 |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| LT3105328T (lt) | 2014-02-11 | 2020-07-10 | The Regents Of The University Of Colorado, A Body Corporate | Daugiakomponentis genomo konstravimas, sudarantis sąlygas crispr |
| EP3134546A4 (en) | 2014-04-24 | 2017-12-06 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| EP3137103B1 (en) * | 2014-04-29 | 2021-10-20 | Bio-Cancer Treatment International Ltd. | Methods and compositions for modulating the immune system with arginase i |
| EP2982758A1 (en) | 2014-08-04 | 2016-02-10 | Centre Hospitalier Universitaire Vaudois (CHUV) | Genome editing for the treatment of huntington's disease |
| EP3186281B1 (en) | 2014-08-28 | 2019-04-10 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
| JP2019508037A (ja) | 2016-02-16 | 2019-03-28 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ | 標的化遺伝子編集を増強するための組成物およびその使用方法 |
| KR102646323B1 (ko) | 2016-05-06 | 2024-03-13 | 이뮤노포지 주식회사 | 제어된 지속 방출을 위한 elp 융합 단백질 |
| TWI878212B (zh) | 2017-12-05 | 2025-04-01 | 瑞典商伊梅爾迪卡製藥公司 | 用於治療精胺酸酶1缺乏症之方法及組合物 |
| BR112022003633A2 (pt) | 2019-08-30 | 2022-06-07 | Aeglea Biotherapeutics Inc | Métodos para produção de arginase 1 recombinante humana e usos da mesma |
| CN119301247A (zh) | 2022-04-11 | 2025-01-10 | 伊梅尔迪卡制药公司 | 精氨酸酶1缺乏症的治疗 |
-
2018
- 2018-12-05 TW TW107143773A patent/TWI878212B/zh active
- 2018-12-05 US US16/210,248 patent/US11717562B2/en active Active
- 2018-12-05 EP EP18821957.0A patent/EP3720476A1/en active Pending
- 2018-12-05 WO PCT/US2018/063982 patent/WO2019113157A1/en not_active Ceased
- 2018-12-05 KR KR1020267007681A patent/KR20260047622A/ko active Pending
- 2018-12-05 CN CN202510809152.4A patent/CN120661640A/zh active Pending
- 2018-12-05 MX MX2020005933A patent/MX2020005933A/es unknown
- 2018-12-05 CN CN201880079119.9A patent/CN111787941A/zh active Pending
- 2018-12-05 CA CA3084801A patent/CA3084801A1/en active Pending
- 2018-12-05 CN CN202510809272.4A patent/CN120643682A/zh active Pending
- 2018-12-05 KR KR1020207019283A patent/KR20200122298A/ko not_active Ceased
- 2018-12-05 JP JP2020531164A patent/JP7827407B2/ja active Active
- 2018-12-05 AU AU2018378485A patent/AU2018378485B2/en active Active
-
2020
- 2020-07-13 MX MX2025006207A patent/MX2025006207A/es unknown
-
2023
- 2023-06-29 US US18/344,083 patent/US12673093B2/en active Active
- 2023-11-27 JP JP2023199616A patent/JP2024028760A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019113157A1 (en) | 2019-06-13 |
| TWI878212B (zh) | 2025-04-01 |
| JP7827407B2 (ja) | 2026-03-10 |
| MX2025006207A (es) | 2025-07-01 |
| US20190167770A1 (en) | 2019-06-06 |
| KR20200122298A (ko) | 2020-10-27 |
| CA3084801A1 (en) | 2019-06-13 |
| US20240009284A1 (en) | 2024-01-11 |
| TW201924715A (zh) | 2019-07-01 |
| CN120643682A (zh) | 2025-09-16 |
| KR20260047622A (ko) | 2026-04-08 |
| US11717562B2 (en) | 2023-08-08 |
| CN120661640A (zh) | 2025-09-19 |
| EP3720476A1 (en) | 2020-10-14 |
| AU2018378485B2 (en) | 2024-06-20 |
| JP2021505620A (ja) | 2021-02-18 |
| JP2024028760A (ja) | 2024-03-05 |
| CN111787941A (zh) | 2020-10-16 |
| AU2018378485A1 (en) | 2020-07-23 |
| US12673093B2 (en) | 2026-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025006207A (es) | Composiciones que contienen arginasa i humana con un cofactor de metal de cobalto para usarse en el tratamiento de la deficiencia de arginasa 1 | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| MY196582A (en) | PD-1/PD-L1 Inhibitors | |
| MX2021010528A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
| PH12019502174A1 (en) | Modulators of pcsk9 expression | |
| PH12019502379A1 (en) | Pd-1/pd-l1 inhibitors | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| MX2018003472A (es) | Moduladores de la expresion de kras. | |
| ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
| EA201591278A1 (ru) | Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы | |
| MX2025003294A (es) | Moduladores de la expresion de apol1 | |
| PH12021552588A1 (en) | Cd73 inhibitors | |
| MX2016005669A (es) | Revestimiento de alginato para tratamiento de tallos. | |
| PH12017500615A1 (en) | Ophthalmic composition comprising cyclosporine and trehalose | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| BR112014000542A2 (pt) | composições de peroxidase eosinofílica e métodos de uso das mesmas | |
| HK1254954A1 (zh) | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 | |
| MY200299A (en) | Composition for improving brain function for neonates | |
| EA202191631A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MY194272A (en) | Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same | |
| AR117094A1 (es) | Moduladores de expresión irf5 | |
| SG10201811078XA (en) | Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| AU2020378127A8 (en) | Compounds as CD73 inhibitors | |
| MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. |